Insulin-like growth factor I diminishes in vivo and in vitro vascular contractility: Role of vascular nitric oxide

Endocrinology

Volumn 137, Issue 5, 1996, Pages 1798-1803

  Walsh, Mary F ^b   Barazi, Muhamad ^b   Pete, Gina ^b   Muniyappa, Ranganath ^b   Dunbar, Joseph C ^b   Sowers, James R ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE METHYL ESTER; NITRIC OXIDE; NORADRENALIN; POTASSIUM CHLORIDE; SOMATOMEDIN C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD FLOWMETRY; CONTROLLED STUDY; ENDOTHELIUM CELL; HORMONAL REGULATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; RESISTANCE BLOOD VESSEL; SMOOTH MUSCLE CONTRACTION; VASCULAR ENDOTHELIUM;

EID: 0030002827     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.137.5.8612517     Document Type: Article

References (48)

1. Jacob R, Barrett E, Plewe G, Fagin KD, Sherwin RS 1989 Acute effects of insulin-like growth factor 1 on glucose and amino acid metabolism in the awake fasted rat. J Clin Invest 83:1717-1721
2. Elahi D, McAloon-Dyke M, Fukagawa NK 1991 Hemodynamic and metabolic responses to human insulin-like growth factor-1 in men. In: Spencer EM (ed) Modern Concepts in Insulin-Like Growth Factors. Elsevier, New York, pp 219-224
3. Sowers JR, Standley PR, Ram JL, Jacober S 1993 Hyperinsulinemia, insulin resistance, and hyperglycemia: contributing factors in the pathogenesis of hypertension and atherosclerosis. Am J Hypertens 6:260S-270S
4. Kahn AM, Siedel CL, Allen JC, O'Neil RG, Shelat H, Song T 1993 Insulin reduces contraction and intracellular calcium concentration in vascular smooth muscle. Hypertension 22:735-742
5. Ram JL, Fares MA, Standley PR, Sowers JR 1993 Insulin inhibits vasopressin-elicited contraction of vascular smooth muscle cells. J Vasc Biol 4:250-254
6. Copeland KC, Sreekuran K 1994 Recombinant human insulin-like growth factor-1 increases forearm blood flow. J Clin Endocrinol Metab 79:230-232
7. Yagi S, Takata S, Kiyokawa H, Yamamoto M, Noto Y, Ikeda T, Hattori N 1992 Effects of insulin on vasoconstrictive responses to norepinephrine and angiotensin II in rabbit femoral artery and vein. Diabetes 37:1064-1067
8. Townsend RR, Yamamoto R, Nickols M, DiPette DJ, Nickols GA 1992 Insulin enhances pressor responses to norepinephrine in rat mesenteric vasculature. Hypertension [Suppl 11] 19:II105-II110
9. Wu H-Y, Young YJ, Yue C-J, Kuang-Yuh C, Hsueh WA, Chan TM 1994 Endothelial-dependent vascular effects of insulin and insulin-like growth factor 1 in the perfused rat mesenteric artery and aortic ring. Diabetes 43:1027-1032
10. Hirschberg R, Brunori G, Koppel J, Guler HP 1993 Effects of insulin like growth factor-1 on renal function in normal men. Kidney Int 43:387-397
11. Guler HP, Eckardt KU, Zapf J, Baver C, Froesch ER 1989 Insulin like growth factor-1 increases glomerular filtration rate and renal plasma flow in man. Acta Endocrinol (Copenh) 121:101-106
12. Delafontaine P, Lou H, Alexander RW 1991 Regulation of insulin-like growth factor 1 messenger RNA levels in vascular smooth muscle cells. Hypertension 18:742-747
13. Tsukahara H, Gordienko DV, Toushoff B, Gelato MC, Goligorsky MS 1994 Direct demonstration of insulin-like growth factor-1-induced nitric oxide production by endothelial cells. Kidney Int 45: 598-604
14. Grover A, Padington C, Wilson MF, Sung BH, Izzo Jr JL, Dandona P 1995 Insulin attenuates norepinephrine-induced venoconstriction. An ultrasonographic study. Hypertension 25:779-784
15. Haylor J, Singh I, El-Nahas AM 1991 Nitric oxide synthesis inhibitor prevents vasodilation by insulin like growth factor 1. Kidney Int 39:333-335
16. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P 1994 Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest 94:2511-2515
17. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD 1994 Insulin-mediated skeletal muscle vasodilation is nitric-oxide-dependent: a novel action of insulin to increase nitric oxide release. J Clin Invest 94:1172-1179
18. Hirschberg R, Kopple J 1989 Evidence that insulin like growth factor 1 increases renal plasma flow and glomerular filtration rate in fasted rats. J Clin Invest 83:326-330
19. Lembo G, Iaccarino G, Rendika V, Volpe M, Trimarco B 1994 Insulin blunts sympathetic vasoconstriction through the α-2-adrenergic pathway in humans. Hypertension 24:429-438
20. Sakai K, Imaizumi T, Masaki H, Takeshita A 1993 Intra-arterial infusion of insulin attenuates vasoreactivity in the human forearm. Hypertension 22:67-73
21. Baron AD, Brechtel-Hook G, Johnson JA, Hardin D 1993 Skeletal muscle blood flow: a possible link between insulin resistance and blood pressure. Hypertension 21:129-135
22. Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL 1991 Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest 87:2246-2252
23. Schultz-Klarr S, Wright-Richey J, Dunbar JC 1994 Effect of insulin-induced hypoglycemia, 2-deoxyglucose-induced glucose cytopenia and hyperglycemia on cardiovascular tone in normal and diabetic rats. J Assoc Acad Minor Phys 5:152-158
24. Peuler JD, Johnson BA, Phare SM, Sowers JR 1993 Sex-specific effects of an insulin secretagogue in stroke-prone hypertensive rats. Hypertension 22:214-220
25. Schultz-Klarr S, Wright-Richey J, Dunbar JC 1994 Plasma glucose, insulin and cardiovascular responses after intravenous and intra-cerebroventricular injection of insulin, 2-deoxyglucose and glucose in rats. Diabetes Res Clin Pract 26:81-89
26. Fryburg DA 1994 Insulin-like growth factor-1 exerts growth hormone and insulin-like actions on human muscle protein metabolism. Am J Physiol 267:E331-E336
27. Van Obberghen E 1994 Signalling through the insulin receptor and the insulin-like growth factor-1 receptor. Diabetologia 37:S125-S134
28. Anderson EA, Mack AL 1993 The vasodilator action of insulin. Implications for the insulin hypothesis of hypertension. Hypertension 21:136-141
29. +-ATPase activity in rat aorta. Diabetologia 36:212-217
30. Standley PR, Ram JL, Sowers JR 1993 Insulin attenuation of vascular smooth muscle calcium responses in Zucker lean and obese rats. Endocrinology 133:1693-1699
31. Hori MT, Fittinghoff M, Tuck ML 1993 Mechanism of insulin attenuation of calcium in cultured vascular smooth muscle cells. J Clin Invest 92:1161-1167
32. Engfeldt P, Hellmer J, Wahrenberg H, Arner P 1988 Effects of insulin on adrenoreceptor binding and the rate of catecholamine-induced lipolysis in isolated human fat cells. J Biol Chem 263:15553-15560
33. Hadcock JR, Port JD, Gelman MS, Malbon CC 1992 Cross-talk between tyrosine kinase and G-protein-linked receptors. Phosphorylation of β2-adrenergic receptors in response to insulin. J Biol Chem 267:26017-26022
34. Shimosawa T, Ando K, Ono A, Takahashi K, Isshiki M, Kondo M, Ogata E, Fujita T 1992 Insulin inhibits norepinephrine overflow from peripheral sympathetic nerve endings. Biochem Biophys Res Commun 188:230-235
35. Moncada S 1994 Nitric oxide. Hypertension 12:S35-S39
36. Michel T, Li GK, Busconi L 1993 Phosphorylation and subcellular translocation of endothelial nitric oxide synthase. Proc Natl Acad Sci USA 90:6252-6256
37. Geng Y-J, Almqvist M, Hansson GK 1994 cDNA cloning and expression of inducible nitric oxide synthetase from rat vascular smooth muscle cells. Biochim Biophys Acta 1218:421-424
38. Dong Z, Qi X, Xie K, Fidler IJ 1993 Protein tyrosine kinase inhibitors decrease induction of nitric oxide synthase activity in lipopolysaccharide-responsive and -non responsive murine macrophages. J Immunol 157:2717-2724
39. Schini VB, Catovsky S, Schray-Utz B, Busse K, Vanhoutte PM 1994 Insulin-like growth factor 1 inhibits induction of nitric oxide synthase in vascular smooth muscle cells. Circ Res 74:24-32
40. Traub O, Van Bibber R 1995 Role of nitric oxide in insulin-dependent diabetes mellitus-related vascular complications. West J Med 162:439-445
41. Archer SL, Huang JM, Hampl V, Nelson DP, Schultz PJ, Weir EK 1994 Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase. Proc Natl Acad Sci USA 91:7583-7587
42. King GL, Goodman AD, Buzrey S, Masis A, Kahn CR 1985 Receptors and growth-promoting effects of insulin and insulin-like growth factors on cells from bovine retinal capillaries and aorta. J Clin Invest 75:1028-1036
43. Bornfeldt KE, Arnquist HJ, Norstedt G 1990 Regulation of insulin-like growth factor-1 gene expression by growth factors in cultured vascular smooth muscle cells. J Endocrinol 125:381-386
44. Murphy LJ, Ghahary A, Chakrabarti S 1990 Insulin regulation of IGF-1 expression in rat aorta. Diabetes 39:657-661
45. Ignarro LJ, Wood KS, Fukuto JM 1991 Continuous basal formation of endothelium-derived relaxing factor and muscle-derived relaxing factor, both of which are nitric oxide. J Cardiovasc Pharmacol 17: 5229-5233
46. Marczin N, Papapetropoulos A, Catravas JD 1993 Tyrosine kinase inhibitors suppress endotoxin- and IL-1 beta-induced NO synthesis in aortic smooth muscle cells. Am J Physiol 265:H1014-H1018
47. Pilz RB, Suhasini M, Idiess S, Meinkoth JL, Boss GR 1995 Nitric oxide and cGMP analogs activate transcription from AP-1-responsive promoters in mammalian cells. FASEB J 9:552-558
48. Hollenberg MD 1994 Tyrosine kinase pathways and the regulation of smooth muscle contractility. Trends Pharmacol Sci 15:108-114